Literature DB >> 23082735

Chemotherapy: What is its role in meningioma?

W J Sherman1, J J Raizer.   

Abstract

While strong evidence exists for the standard therapy for meningiomas, inclusive of surgery and/or radiation therapy, for those tumors which recur, progress or are inoperable, the optimal medical therapies are yet to be elucidated. This article reviews the current literature for chemotherapeutic options for this subset of tumors, including cytotoxic agents, biologic agents, targeted molecular agents and hormonal agents. At this point in time, the most data is with hydroxyurea and somatostatin, although further trials with combination and targeted molecular therapies are still underway.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23082735     DOI： 10.1586/ern.12.108

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN： 1473-7175            Impact factor:   4.618


  8 in total

1.  Consensus core clinical data elements for meningiomas (v2021.1).

Authors:  Farshad Nassiri; Justin Z Wang; Karolyn Au; Jill Barnholtz-Sloan; Michael D Jenkinson; Kate Drummond; Yueren Zhou; James M Snyder; Priscilla Brastianos; Thomas Santarius; Suganth Suppiah; Laila Poisson; Francesco Gaillard; Mark Rosenthal; Timothy Kaufmann; Derek S Tsang; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

2.  The importance of microsurgery in childhood meningioma: a case report.

Authors:  L E Kwee; M L C van Veelen-Vincent; E M C Michiels; J M Kros; R Dammers
Journal:  Childs Nerv Syst       Date:  2014-07-18       Impact factor: 1.475

3.  Microsurgical management of primary jugular foramen meningiomas: a series of 22 cases and review of the literature.

Authors:  Jie Tang; Liwei Zhang; Junting Zhang; Zhen Wu; Xinru Xiao; Dabiao Zhou; Guijun Jia; Wang Jia
Journal:  Neurosurg Rev       Date:  2016-06-23       Impact factor: 3.042

4.  Metastatic meningioma presenting as cancer of unknown primary.

Authors:  Vinay Gupta; Wilson I Gonsalves; Steven I Robinson
Journal:  Rare Tumors       Date:  2013-12-16

5.  Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.

Authors:  Melissa Schmidt; Andreas Mock; Christine Jungk; Felix Sahm; Anna Theresa Ull; Rolf Warta; Katrin Lamszus; Konstantinos Gousias; Ralf Ketter; Saskia Roesch; Carmen Rapp; Sebastian Schefzyk; Steffi Urbschat; Bernd Lahrmann; Almuth F Kessler; Mario Löhr; Christian Senft; Niels Grabe; David Reuss; Philipp Beckhove; Manfred Westphal; Andreas von Deimling; Andreas Unterberg; Matthias Simon; Christel Herold-Mende
Journal:  Oncotarget       Date:  2016-03-22

6.  Is an Immunosuppressive Microenvironment a Characteristic of Both Intra- and Extraparenchymal Central Nervous Tumors?

Authors:  Amina Soltani; Bela Kajtar; El Husseiny Mohamed Mahmud Abdelwahab; Anita Steib; Zsolt Horvath; Laszlo Mangel; Luca Jaromi; Judit E Pongracz
Journal:  Pathophysiology       Date:  2021-01-08

7.  Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo.

Authors:  Tao Yu; Junguo Cao; Montadar Alaa Eddine; Mahmoud Moustafa; Andreas Mock; Cihan Erkut; Amir Abdollahi; Rolf Warta; Andreas Unterberg; Christel Herold-Mende; Gerhard Jungwirth
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

8.  A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.

Authors:  Priya Kumthekar; Sean Aaron Grimm; Roxanne T Aleman; Marc C Chamberlain; David Schiff; Patrick Y Wen; Fabio Massaiti Iwamoto; Demirkan Besim Gursel; David A Reardon; Benjamin Purow; Masha Kocherginski; Irene Helenowski; Jeffrey J Raizer
Journal:  Neurooncol Adv       Date:  2022-08-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.